Alnylam Provides Key 2012 Goals for RNAi Therapeutics Pipeline - Alnylam
Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis - Alnylam
Alnylam and Arrowhead Form Collaboration and Licensing Agreement - Alnylam
